Sarepta Therapeutics (NASDAQ:SRPT) Receives Outperform Rating from Raymond James
Raymond James restated their outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a report released on Thursday morning, Marketbeat Ratings reports. They currently have a $150.00 price objective on the biotechnology company’s stock. Other research analysts also recently issued reports about the stock. Piper Sandler lowered their price objective on shares […]
More Stories
Brokerages Set Mettler-Toledo International Inc. (NYSE:MTD) Target Price at $1,363.75
Mettler-Toledo International Inc. (NYSE:MTD – Get Free Report) has received an average rating of “Reduce” from the eight analysts that...
Polianta Ltd Increases Stock Holdings in The Mosaic Company (NYSE:MOS)
Polianta Ltd increased its holdings in shares of The Mosaic Company (NYSE:MOS – Free Report) by 30.4% during the 3rd...
Polianta Ltd Trims Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)
Polianta Ltd reduced its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 19.5% in the third...
Recent Investment Analysts’ Ratings Updates for eBay (EBAY)
A number of research firms have changed their ratings and price targets for eBay (NASDAQ: EBAY): 10/11/2024 – eBay had...
Polianta Ltd Purchases New Position in Target Co. (NYSE:TGT)
Polianta Ltd acquired a new position in shares of Target Co. (NYSE:TGT – Free Report) during the 3rd quarter, according...
Polianta Ltd Makes New $1.22 Million Investment in Tyson Foods, Inc. (NYSE:TSN)
Polianta Ltd bought a new position in shares of Tyson Foods, Inc. (NYSE:TSN – Free Report) in the 3rd quarter,...